MethylGene and Pharmion report favorable results for Phase 2 single-agent studies in relapsed or refractory lymphomas

News | 12. 09. 2007

MethylGene Inc. (TSX:MYG) and Pharmion Corporation (Nasdaq: PHRM) today announced preliminary data from two ongoing Phase II studies with MGCD0103, the Companies' novel, isotype- selective histone deacetylase (HDAC) inhibitor, as a single-agent in the treatment of Hodgkin lymphoma (HL) and non- Hodgkin lymphoma (NHL). Data from these studies were presented today at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH).